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Background: The identification of genetic determinants of Crohn’s disease (CD) remains a challenge. This study 
aimed at identifying new candidate susceptibility genes for CD by integrating known disease loci with gene 
expression in unaffected colon biopsies of CD patients. We focused on characterizing one of the candidate genes, 
metallothionein (MT), which belong to a family of highly conserved stress proteins comprising 
immunomodulating properties. 
Methods: Sixteen CD patients and 11 controls were subjected to microarray analysis using a focus microarray 
(VIB Crohn 7K2) containing 6,779 expressed sequence tags. The expression of MT was analyzed by quantitative 
PCR and immunohistochemistry. To model lowered MT expression in vitro, a colonic epithelial cell line 
expressing small interfering RNA against MT was generated. The gene for MRE-binding transcription factor 1 
(MTF1) was screened for mutations in 96 CD patients and the influence of a polymorphism on transcriptional 
activity was assessed in a luciferase reporter assay. 
Results: Eighteen differentially expressed genes were identified. Metallothionein mRNA expression was reduced 
in colon biopsies (P=0.008) and in PBMCs (P=0.026) of patients with colonic involvement. This observation was 
confirmed in ileal biopsies by immunohistochemistry (P=0.046). MT-knockdown HT29 cells showed a reduced 
IL8 secretion in response to bacterial challenge. Sequence analysis of the main transcriptional regulator of MTs, 
MTF1, revealed two coding mutations: Asp63Glu in 5 patients and Glu385Lys in 2 patients. In addition, a 
frequent (29%) polymorphism at the splice site junction between exon 8 and 9 (c.1270A>G) was found. An 
intronic polymorphism (IVS1-128A>T) was significantly associated with colonic disease (Chi-square: 8.297, 
P=0.004). Moreover, this polymorphism was shown to influence the transcription of a reporter gene, suggesting 
allele specific transcription of MTF1 which could be responsible for the reduced MT expression observed in 
colonic CD.  
Conclusions: We showed that deficient basal MT expression in CD patients with colonic involvement is, at least 
in part, genetically determined. We identified MTF1 (located within the IBD7 locus) as a new disease-modifying 
gene. 
